Anti p akt1 2 3 sc 7985 r

Enhanced chemiluminescence reagents and nitrocellulose membranes (Hybond-C extra) were from Amersham Pharmacia Biotech, Inc (Piscataway, NJ). The following antibodies were used: anti–HIF-1α (NB100-479) and anti–HIF-2α (NB100-122) from Novus Biologicals (Cambridge, UK); anti-CD105 (PA5-12511), anti-PCNA (PA5-27214), and anti-SB3 (PA5-30164) from ThermoFisher Scientific (Rockford, IL); anti–α-SMA (M0851) was from DAKO (Agilent, St Clara, CA); anti-SB3 (GTX32866) was from GeneTex (Irvine, CA); anti-F4/80 (14-4801-82) was from eBioscience (Affymetrix, St Clara, CA); anti-YAP (sc-15407), anti-c-MYC (sc-788), anti-SB3 (sc21767), anti-p53 (sc-6243), anti-p21 (sc-817), anti-ERK (sc-94), anti-JNK (sc-571), antivinculin (sc-73614), anti–p-Akt1/2/3 (sc-7985-R), and anti-Akt1/2/3 (sc-8312) were from Santa Cruz Biotechnology (Dallas, TX); anti-phospho-ERK (extracellular-regulated kinase, [4696]) and anti–anti-phospho-JNK (c-Jun aminoterminal kinase [9255]) were from Cell Signaling Technology (Danvers, MA); and anti–β-actin (A5441) was from Sigma Aldrich (St. Louis, MO). HiPerfect Transfection reagent was from Qiagen (Hilden, Germany), Lipofectamine 2000 was from Invitrogen-Life Technologies (Carlsbad, CA), plasmid DNA purification NucleoBond XtraMIDI was from Macherey-Nagel (Allentown, PA), and pCMV6-entry vectors were from Origene (Rockville, MD).